Skip to search formSkip to main contentSkip to account menu

Consolidation with alemtuzumab improves progression‐free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission – long‐term follow‐up of a randomized phase III trial of the…

Despite toxicity, MRD reduction by alemtuzumab consolidation translates into a significantly improved long‐term clinical outcome.
View on Wiley (opens in a new tab)

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial

This analysis supports the hypothesis that for the evaluated regimens, a correlation exists between capecitabine-attributed ST and treatment efficacy regarding DCR, PFS, and OS.
View on Nature (opens in a new tab)

Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany—data from the Prospective Tumour Registry Lymphatic Neoplasms†

The Tumour Registry Lymphatic Neoplasms prospectively collects data on the treatment of patients with lymphoid B‐cell neoplasm as administered by office‐based haematologists in Germany, and 91% of first‐line treatments were successful (40% complete response).
View on Wiley (opens in a new tab)

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group
View on Nature (opens in a new tab)

Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma

Re-RT/BEV→BEV is safe, feasible and effective and deserves further prospective evaluation.
View on Springer (opens in a new tab)

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer

Severe leukopenia seems avoidable in weekly scheduled single-agent docetaxel and may serve as an important treatment option, particularly in elderly patients and patients with a reduced performance status.
View on PubMed (opens in a new tab)

Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry

Her2-positive patients, who initially respond to palliative treatment with trastuzumab, can achieve a long-term tumor remission of several years.
View on Springer (opens in a new tab)

High Efficacy and Low Toxicity of Weekly Docetaxel Given as First-Line Treatment for Metastatic Breast Cancer

The weekly administration of docetaxel is highly efficient and safe as first-line treatment for MBC and may serve as an important treatment option specifically in elderly patients and patients with a reduced performance status.
View on PubMed (opens in a new tab)

Early and Risk-Adapted Therapy with Fludarabine in High-Risk Binet Stage A CLL Patients Prolongs Progression Free Survival but Not Overall Survival: Results of the CLL1 Protocol of the German CLL…

The CLL1 protocol, a randomized phase III trial of the GCLLSG, was conducted to assess if the early use of fludarabine prolongs progression free survival (PFS) in high risk (HR) CLL pts, but not the OS in this group of patients.
View via Publisher (opens in a new tab)

Similar effectiveness of R‐CHOP‐14 and ‐21 in diffuse large B‐cell lymphoma—data from the prospective German Tumour Registry Lymphatic Neoplasms

Dose‐dense two‐weekly ‘R‐CHOP‐14’ was not superior over three‐weekly’ in randomised clinical trials (RCTs) and real‐world data on effectiveness of R‐CHop‐14 and R‐ CHOP‐21 in patients with DLBCL treated in German routine practice is presented.
View on Wiley (opens in a new tab)
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)